Kasturi Siddhanta

Kasturi Siddhanta

Auto-generated profile, based on publicly available information

Kasturi Siddhanta

University of Nebraska Medical Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Advanced Healthcare Materials
Verified
Journal Article
Open access
CJChinmay Jogdeo
Chinmay Jogdeo
Sudipta PanjaSudipta Panja
Sudipta Panja
SKShrey Kanvinde
Shrey Kanvinde
EKEkta Kapoor
Ekta Kapoor
KSKasturi Siddhanta
Kasturi Siddhanta
DODavid Oupicky
David Oupicky
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale‐up. This review highlights the advances of the last decade in lipid‐based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic‐based combinations for targeted therapy in cancer and inflammatory diseases.

13 March 2025 in Biomaterials
Verified
Journal Article
Closed access
Sudipta PanjaSudipta Panja
Sudipta Panja
EKEkta Kapoor
Ekta Kapoor
KSKasturi Siddhanta
Kasturi Siddhanta
CJChinmay M. Jogdeo
Chinmay M. Jogdeo
DSDiptesh Sil
Diptesh Sil
DODavid Oupicky
David Oupicky

5 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKasturi Siddhanta
Kasturi Siddhanta
AMAtefehsadat Monirvaghefi
Atefehsadat Monirvaghefi
ASAditya Sundar
Aditya Sundar
BPBraeden R. Pinkerton
Braeden R. Pinkerton
NKNeha Kumari
Neha Kumari
DODavid Oupicky
David Oupicky
Inhalation RNA therapy offers to transform treatment of pulmonary diseases, yet mucus trapping, immune clearance, and navigation of heterogeneous lung tissue architecture still prevents RNA from reaching its target cells. Here, we develop perfluorocarbon (PFC) RNA nanocapsules that show negligible immune clearance, minimal inflammatory response, and efficient mucus transport, while passively homing to lung epithelial and tumor cells. After a single aerosolized dose in orthotopic lung metastasis model, more than 60% of tumor cells and most type II alveolar and bronchial epithelial cells internalized the nanocapsules, with observed pulmonary retention exceeding 48 h. The nanocapsule provoke negligible cytokine release, enabling repeated dosing. Treatment with therapeutic miR34-a suppresses metastatic outgrowth, potentiates anti-tumor immunity, and almost doubles median survival relative to control paclitaxel chemotherapy. By combining unique PFC disposition with RNA versatility, the delivery platform overcomes the main biological barriers for inhalable RNA medicines and opens a translatable path for treating diverse pulmonary diseases.

11 December 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
DODavid Oupicky
David Oupicky
KSKasturi Siddhanta
Kasturi Siddhanta
NKNeha Kumari
Neha Kumari
RSRahul Singh
Rahul Singh
BPBraeden Pinkerton
Braeden Pinkerton
Ling DingLing Ding
Ling Ding
Systemically administered lipid nanoparticles (LNPs) predominantly target the liver, limiting their use for extrahepatic applications. Here, we introduce cyclam-based ionizable lipids that confer selective lung tropism after intravenous dosing. A ten-member library spanning three linker chemotypes and varied hydrophobic tails produced LNPs that consistently delivered mRNA to the lung. Lipids with aromatic linkers yielded compact nanoparticles (50–80 nm), with high encapsulation and RNA recovery, and outperformed DLin-MC3-DMA in vitro and in vivo. In Ai9 reporter mice, two intravenous doses of Cre mRNA formulated with lead cyclam lipid achieved ~30% lung editing with minimal off-organ activity. Structure–property analyses showed that increasing lipophilicity and aromatic content correlated inversely with particle size and positively with encapsulation, establishing design rules for macrocycle-guided delivery. Cyclam-based ionizable lipids thus enable systemically administered, lung-selective expression and provide a versatile platform for mRNA and gene-editing therapies.